Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates
Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
Catalent reports Q1 EPS (13c), consensus 5c
Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant
Catalent reports Q1 loss, misses market expectations
Catalent (NYSE: CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations. The
Zacks.com on MSN
12d
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...
bovnews
14d
The Catalent Inc Stock Thriller: Decoding the Mystery Behind CTLT’s Recent Movements
Robert W. Baird has recently raised Catalent Inc (
CTLT
) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock ...
20h
Catalent: Fiscal Q1 Earnings Snapshot
(CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of ...
news.stocktradersdaily
5d
How the (CTLT) price action is used to our Advantage
Check the time stamp on this data. Updated AI-Generated Signals for Catalent Inc. (CTLT) available here: CTLT.
13d
on MSN
Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update)
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Catalent
Novo Nordisk
Feedback